[go: up one dir, main page]

LT3749308T - Klasikine fabri liga sergančių pacientų gydymas migalastatu - Google Patents

Klasikine fabri liga sergančių pacientų gydymas migalastatu

Info

Publication number
LT3749308T
LT3749308T LTEPPCT/US2019/016853T LTUS2019016853T LT3749308T LT 3749308 T LT3749308 T LT 3749308T LT US2019016853 T LTUS2019016853 T LT US2019016853T LT 3749308 T LT3749308 T LT 3749308T
Authority
LT
Lithuania
Prior art keywords
migalastat
classical
patients
treatment
fabri
Prior art date
Application number
LTEPPCT/US2019/016853T
Other languages
English (en)
Inventor
Jay Barth
Elfrida Benjamin
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65494622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3749308(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of LT3749308T publication Critical patent/LT3749308T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2019/016853T 2018-02-06 2019-02-06 Klasikine fabri liga sergančių pacientų gydymas migalastatu LT3749308T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862626992P 2018-02-06 2018-02-06
PCT/US2019/016853 WO2019157056A1 (en) 2018-02-06 2019-02-06 Treatment of patients with classic fabry disease

Publications (1)

Publication Number Publication Date
LT3749308T true LT3749308T (lt) 2024-02-12

Family

ID=65494622

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/016853T LT3749308T (lt) 2018-02-06 2019-02-06 Klasikine fabri liga sergančių pacientų gydymas migalastatu

Country Status (20)

Country Link
US (1) US20210038579A1 (lt)
EP (2) EP3749308B1 (lt)
JP (2) JP2021512896A (lt)
KR (1) KR20200128675A (lt)
CN (1) CN112203657A (lt)
AR (1) AR114392A1 (lt)
AU (2) AU2019217603A1 (lt)
DK (1) DK3749308T3 (lt)
ES (1) ES2969263T3 (lt)
FI (1) FI3749308T3 (lt)
HR (1) HRP20240025T1 (lt)
HU (1) HUE064761T2 (lt)
LT (1) LT3749308T (lt)
PL (1) PL3749308T3 (lt)
PT (1) PT3749308T (lt)
RS (1) RS65103B1 (lt)
SI (1) SI3749308T1 (lt)
SM (1) SMT202400027T1 (lt)
TW (1) TWI869336B (lt)
WO (1) WO2019157056A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2533050T6 (pl) 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
DK3470077T3 (da) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
CA3224546A1 (en) 2017-05-30 2018-12-06 Jeff Castelli Use of migalastat in the treatment of fabry patients having renal impairment
JP7555818B2 (ja) 2018-02-06 2024-09-25 アミカス セラピューティックス インコーポレイテッド 妊娠患者におけるファブリー病の治療のためのミガラスタットの使用
KR20220044560A (ko) 2019-08-07 2022-04-08 아미쿠스 세라퓨틱스, 인코포레이티드 Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
PL2533050T6 (pl) * 2006-05-16 2016-05-31 Amicus Therapeutics Inc Możliwości leczenia choroby Fabry'ego
AU2008232614A1 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
DK3470077T3 (da) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Fremgangsmåde til forudsigelse af respons på behandling af sygdomme med farmakologiske chaperoner
CN114159436A (zh) * 2016-03-22 2022-03-11 阿米库斯治疗学公司 治疗在gla基因中具有g9331a突变的患者的法布里病的方法
IL313907A (en) * 2016-07-19 2024-08-01 Amicus Therapeutics Inc Treatment of Fabry disease in patients experienced with ERT-NAIVE and ERT
WO2019017938A1 (en) * 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES

Also Published As

Publication number Publication date
AU2019217603A1 (en) 2020-09-24
WO2019157056A1 (en) 2019-08-15
CA3090499A1 (en) 2019-08-15
WO2019157056A8 (en) 2020-12-03
DK3749308T3 (da) 2024-01-22
AR114392A1 (es) 2020-09-02
HUE064761T2 (hu) 2024-04-28
EP3749308B1 (en) 2023-10-25
EP4316589A3 (en) 2024-04-24
PT3749308T (pt) 2024-01-25
PL3749308T3 (pl) 2024-03-25
JP2024026080A (ja) 2024-02-28
TW201944998A (zh) 2019-12-01
TWI869336B (zh) 2025-01-11
JP2021512896A (ja) 2021-05-20
KR20200128675A (ko) 2020-11-16
SMT202400027T1 (it) 2024-03-13
US20210038579A1 (en) 2021-02-11
EP3749308A1 (en) 2020-12-16
ES2969263T3 (es) 2024-05-17
FI3749308T3 (fi) 2024-01-18
EP4316589A2 (en) 2024-02-07
HRP20240025T1 (hr) 2024-03-29
AU2025200074A1 (en) 2025-01-30
RS65103B1 (sr) 2024-02-29
CN112203657A (zh) 2021-01-08
SI3749308T1 (sl) 2024-03-29

Similar Documents

Publication Publication Date Title
LT3749308T (lt) Klasikine fabri liga sergančių pacientų gydymas migalastatu
IL281773A (en) Ophthalmic composition for treatment of dry eye disease
IL271046A (en) Compounds for treating huntington's disease
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
SI3773558T1 (sl) Kombinirano zdravljenje artritične bolezni
EP3606535A4 (en) TREATMENT OF INFLAMMATORY INTESTINAL DISEASES WITH 2'-FUCOSYLLACTOSE COMPOUNDS
EP3802557A4 (en) THERAPEUTIC TREATMENT OF MICROSATELLITE-UNSTABLE CANCER
LT4176877T (lt) Pacientų, sergančių fabri liga, širdies funkcijos gerinimo ir (arba) stabilizavimo būdai
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
MA53553A (fr) Traitement post-chirurgical de la douleur
HUE058921T2 (hu) Bisz-kolin-tetratiomolibdát wilson-betegség kezelésére
IL281022A (en) Treatment of nsclc patients refractory for anti-pd-1 antibody
HUE059387T2 (hu) Parkinson-kór kezelése
MA42287A (fr) Traitement de patients atteints de diabète sucré de type 2
EP3634370A4 (en) Treatment of cutaneous disorders
DK3886858T3 (da) Forbindelser til behandling af øjensygdomme forbundet med for megen vaskularisering
MX2024003906A (es) Vedolizumab para el tratamiento de pacientes pediatricos.
MA41782A (fr) Traitement de patients atteints de diabète de type 2
IL281663A (en) Therapeutic uses of atomic quantum clusters
EP3458045A4 (en) TREATMENT OF MÉNIÈRE'S DISEASE
EP3752113C0 (en) SURGICAL GAUZE
EP3630185A4 (en) Treatment of neuroinflammatory disease
IL282869A (en) Use of tivozanib to treat subjects with refractory cancer
EP4038180C0 (en) TREATMENT OF CHRONIC SEPTIC GRANULOMATOSIS